A Novel Adenosine A2a Receptor Agonist Attenuates the Progression of Monocrotaline-induced Pulmonary Hypertension in Rats

@article{Alencar2013ANA,
  title={A Novel Adenosine A2a Receptor Agonist Attenuates the Progression of Monocrotaline-induced Pulmonary Hypertension in Rats},
  author={Allan K. N. Alencar and S. L. Pereira and Flavia E. da Silva and V. Cunha and L. M. Lima and R. Tesch and Carlos M R Sant'Anna and C. Fraga and E. Barreiro and R. T. Sudo and G. Zapata-Sudo},
  journal={Journal of Pulmonary and Respiratory Medicine},
  year={2013},
  volume={2013}
}
Background and purpose: Pulmonary hypertension is characterized by enhanced pulmonary vascular resistance, Right Ventricular Hypertrophy (RVH), and increased Right Ventricular Systolic Pressure (RVSP). This study examined the therapeutic effects of (E)-N'-(3,4-dimethoxybenzylidene)-3,4-dimethoxy-N-methylbenzohydrazide (LASSBio-1366) on monocrotaline-induced pulmonary hypertension in rats. Experimental approach: Pulmonary hypertension was induced in male Wistar rats by a single intraperitoneal… Expand
Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline‐induced pulmonary hypertension in rats
TLDR
The effects of a N‐acylHydrazone derivative, 3,4‐dimethoxyphenyl‐N‐methyl‐benzoylhydrazide (LASSBio‐1359), on monocrotaline (MCT)‐induced pulmonary hypertension in rats are investigated. Expand
Targeting of the Adenosine Receptors as A Novel Strategy for the Treatment of Arterial Hypertension
Hypertension is the most common risk factor for cardiovascular disease, which is the leading cause of death in industrialized societies. More than 25% of the adult population had hypertension inExpand
A2A-D2 Heteromers on Striatal Astrocytes: Biochemical and Biophysical Evidence
TLDR
Biochemical and biophysical evidence is provided confirming that receptor–receptor interaction between A2A and D2 receptors at the astrocyte plasma membrane is based on A 2A-D2 heteromerization, the first direct demonstration of the ability of native A1 and D1 receptors to heteromerize on glial cells. Expand
Trends in the Epidemiological Study of the Most Common Pulmonary and Respiratory Disorders: A Systematic Overview
TLDR
Though many novel therapies are obtained these days, an understanding of risk factors is required if prevention strategies, such as chemoprophylaxis and environmental control measures are widely applicable and cost-effective. Expand

References

SHOWING 1-10 OF 30 REFERENCES
A novel Ca2+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension.
TLDR
LASSBio-1289 was effective in attenuating MCT-induced PAH in rats, and its beneficial effects were likely mediated by the inhibition of extracellular Ca( 2+) influx through L-type voltage-gated Ca(2+) channels in the pulmonary artery. Expand
Nicorandil Attenuates Monocrotaline-Induced Vascular Endothelial Damage and Pulmonary Arterial Hypertension
TLDR
Nicorandil attenuated MCT-induced vascular endothelial damage and PAH through production of eNOS and anti-apoptotic factors, suggesting that nicor andil might have a promising therapeutic potential for PAH. Expand
Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.
TLDR
It is concluded that rosuvastatin inhibits monocrotaline-induced pulmonary hypertension through normalization of Akt, eNOS and DDAH2 expressions, and decreasing the level of ADMA. Expand
Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline‐induced pulmonary hypertension in rats
TLDR
The effects of a N‐acylHydrazone derivative, 3,4‐dimethoxyphenyl‐N‐methyl‐benzoylhydrazide (LASSBio‐1359), on monocrotaline (MCT)‐induced pulmonary hypertension in rats are investigated. Expand
Absence of the Adenosine A2A Receptor Confers Pulmonary Arterial Hypertension and Increased Pulmonary Vascular Remodeling in Mice
TLDR
Extracellular adenosine acting at A2ARs represents an important regulatory mechanism to control the development of PAH and pulmonary vascular remodeling and associated increased smooth muscle proliferation and collagen deposition. Expand
CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation.
TLDR
It is proposed that adenosine A(2A) receptor agonists such as CGS 21680 may be useful in the treatment of various inflammatory diseases. Expand
Antihypertensive profile of 2-thienyl-3,4-methylenedioxybenzoylhydrazone is mediated by activation of the A2A adenosine receptor.
TLDR
The synthesis and antihypertensive profile of LASSBio-1027, a new analogue of the lead compound 3,4-methylenedioxybenzoyl-2-thienylhydrazone, represents a potential strategy for the treatment of arterial hypertension. Expand
The Effect of Adenosine A2A Receptor Antagonists on Hydroxyl Radical, Dopamine, and Glutamate in the Striatum of Rats with Altered Function of VMAT2
TLDR
The methylxanthine A2A receptor antagonists bearing properties of MAO-B inhibitor, like CSC, may cause a risk of oxidative stress resulting from dysfunctional DA storage mechanism in early PD. Expand
Treatment of pulmonary arterial hypertension with targeted therapies
TLDR
The pharmacological agents currently available for the treatment of PAH are highlighted and a number of investigative approaches focusing on these targets are in active development are discussed. Expand
Isolated rat inferior mesenteric artery response to adenosine: possible participation of Na+/K+-ATPase and potassium channels.
TLDR
Results indicate that in the isolated rat inferior mesenteric artery, adenosine produces endothelium-independent relaxation, which is partly induced by activation of smooth muscleAdenosine A2A receptors, and further mediated by the activation of smoother muscle Na+/K+-ATPase and opening of mixed population of K+ channels. Expand
...
1
2
3
...